United Therapeutics Corporation
UTHR
$515.46
-$12.45-2.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.49% | 5.87% | 10.61% | 13.50% | 17.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.49% | 5.87% | 10.61% | 13.50% | 17.62% |
| Cost of Revenue | 28.93% | 29.15% | 24.12% | 17.09% | 16.21% |
| Gross Profit | -0.78% | 2.99% | 8.98% | 13.06% | 17.80% |
| SG&A Expenses | 13.11% | 12.97% | 15.33% | 15.58% | 16.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.20% | 12.86% | 16.91% | 13.64% | 13.40% |
| Operating Income | -9.13% | -1.31% | 4.42% | 13.36% | 22.14% |
| Income Before Tax | -2.72% | 2.86% | 11.36% | 15.89% | 15.41% |
| Income Tax Expenses | -30.09% | -9.03% | 10.26% | 20.70% | 13.02% |
| Earnings from Continuing Operations | 5.54% | 6.34% | 11.68% | 14.47% | 16.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.54% | 6.34% | 11.68% | 14.47% | 16.15% |
| EBIT | -9.13% | -1.31% | 4.42% | 13.36% | 22.14% |
| EBITDA | -7.96% | -0.53% | 5.07% | 13.87% | 22.56% |
| EPS Basic | 9.29% | 8.18% | 14.09% | 17.16% | 19.89% |
| Normalized Basic EPS | -5.31% | 2.15% | 7.88% | 18.26% | 29.08% |
| EPS Diluted | 9.13% | 8.13% | 13.45% | 15.91% | 17.75% |
| Normalized Diluted EPS | -5.42% | 2.18% | 7.37% | 17.05% | 26.68% |
| Average Basic Shares Outstanding | -3.40% | -1.62% | -1.99% | -2.46% | -3.24% |
| Average Diluted Shares Outstanding | -3.30% | -1.60% | -1.44% | -1.28% | -1.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |